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INTRODUCTION
Juvenile myelomonocytic leukaemia ( JMML) is a rare and 
aggressive stem cell disease of early childhood.1 RAS activa-
tion constitutes the core component of oncogenic signalling. 
In addition, leukemic blasts in one-fourth of JMML patients 
present with monosomy 7, and more than half of patients 
show elevated age-adjusted foetal haemoglobin (HbF) levels. 
Haematopoietic stem cell transplantation is the current 
standard-of-care and results in an event-free survival rate of 
50-60%, indicating that novel molecular-driven therapeutic 
options are urgently needed. Cancer research in the past 
decades mainly focused on aberrations in protein-coding 
genes at the DNA level. However, only 2% of the genome 
codes for proteins, whereas up to 75% of the human DNA 
is capable of being transcribed into RNA.2 The majority of 
RNA transcripts should thus be classified as non-coding 
RNA and an overwhelming amount of research already 
showed their involvement in health and disease. Long non- 
coding RNAs (lncRNAs) are one of the most recently dis- 
covered classes of RNA genes with a minimum length of 
200 nucleotides. Several lncRNAs have been discovered that 
play a crucial role in oncogenesis and point to the fact that 
non-coding regions should not be neglected when studying 
cancer biology. 
LIN28B OVEREXPRESSION DEFINES 
A NOVEL FOETAL-LIKE SUBGROUP OF 
JMML
Using gene expression profiling in a series of 82 patient 
samples, we identified a previously unrecognised molecular 
subgroup characterised by high LIN28B expression.3 LIN28B 
overexpression was significantly correlated with higher HbF 
levels, whereas patients with monosomy 7 seldom showed 
enhanced LIN28B expression (Figure 1). This finding gives 
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a biological explanation of why patients with monosomy 
7 are rarely diagnosed with high age-adjusted HbF levels. 
In addition, this new foetal-like JMML subgroup presented 
with reduced levels of most members of the let-7 microRNA 
family and showed characteristic overexpression of genes 
involved in foetal haematopoiesis and stem cell self-renewal. 
Lastly, high LIN28B expression was associated with poor 
clinical outcome in our JMML patient series but was not 
independent from other prognostic factors such as age and 
age-adjusted HbF levels. In conclusion, we identified elevated 
LIN28B expression as a hallmark of a novel foetal-like sub-
group in JMML. 
Interestingly, LIN28B is normally only active before birth. 
After birth, LIN28B is turned off but is known to be reac- 
tivated in different types of adult cancer. This specificity is 
an important feature for the development of new therapies. 
Indeed, the Holy Grail in cancer treatment is the develop-
ment of drugs that only target the diseased cells but not 
the healthy cells. Since LIN28B is only active in cancer cells 
after birth, the possibilities for developing targeted therapies 
increase – also in JMML. 
LIN28B IS OVEREXPRESSED IN SPECIFIC 
SUBTYPES OF PAEDIATRIC LEUKAEMIA 
AND REGULATES LNCRNA H19
Given the involvement of LIN28B in a variety of solid paedi-
atric cancers, we conducted a meta-analysis of LIN28B levels 
using publicly available gene expression data of 1,361 paedi-
atric leukaemia samples. Interestingly, this analysis revealed 
LIN28B overexpression in 102 childhood leukaemia patients 
(7.5%), suggesting oncogenic activity for LIN28B in the con-
text of paediatric haematological diseases (Figure 2). As the 
mode of action of LIN28B during normal and malignant 
haematopoiesis is currently still largely unknown, we sub- 
sequently analysed the transcriptional consequences of 
LIN28B modulation on normal and malignant haematopoietic 
cells and identified the long non-coding RNA (lncRNA) H19 
as the first LIN28B-regulated lncRNA.4
THE LNCRNA LANDSCAPE IN JMML
After the identification that LIN28B expression is linked to 
the expression of lncRNA H19, we investigated expression 
profiles of 23,042 lncRNAs in a cohort of 44 JMML patients. 
We identified several lncRNAs that are differentially expressed 
between patients and healthy donors and between specific 
JMML subgroups. A total of 295 differentially expressed 
lncRNAs were identified between patient samples and healthy 
controls. Remarkably, through advanced bioinformatics we 
showed that the most important lncRNAs are strongly related 
to myeloid cell biology and networks deregulated in MLL- 
rearranged paediatric leukaemia, and thus warrant further 
research. Diverse JMML subgroups show a distinct lncRNA 
expression profile, although the number of significantly 
differentially expressed genes is less than when comparing 
patients to healthy donors. However, interesting lncRNAs 
putatively involved in distinct biological processes, such as 
the regulation of foetal haemoglobin levels in JMML patients, 
could be identified. We hypothesise that a relatively straight-
forward mutational landscape interacts with a more complex 
landscape of lncRNAs in the pathogenesis of JMML. This 
paves the way for further functional research on the role of 
lncRNAs in JMML biology, and their diagnostic or therapeutic 
application. 
CONCLUSIONS
To improve the survival rates, new therapeutics for JMML 
need to be generated and tested. Bottom-up therapeutic 
development requires a profound biological understanding 
of the disease, which is currently lacking. In the aftermath 
of The Human Genome Project, researchers realised that 
there is more to disease than DNA alone. Indeed, cancer 
development is a complex interplay between DNA, RNA, 
proteins, metabolites, methylation, and the environment. 
FIGURE 1. Circos plot representing the relationships among 
LIN28B expression, HbF level, age at diagnosis, monosomy 7, 
and RAS mutational status in 69 JMML patients with complete 
data available. Quadr. neg., quadruple negative. Figure origi-
nally published in Blood.3
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Because few studies analysed the coding and non-coding 
RNA expression in JMML, we aimed to unravel the biology 
of the disease using transcriptomics. 
The generated results can fuel research in different scientific 
domains. First, the role of LIN28B overexpression in paedi-
atric leukaemia should be further examined and its thera-
peutic applicability evaluated. Second, the identified upstream 
and downstream effectors of LIN28B, both coding and non- 
coding, can now be examined further. Finally, other resear-
chers can use the datasets to look at them from a different 
perspective, since all data are publicly available. 
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FIGURE 2. Log2 LIN28B expression values in fourteen publicly available paediatric leukemia datasets visualised using SinaPlot. 
Each dot is a patient and red dots represent values above the microarray average. The numbers on top represent the percen-
tage of patients with LIN28B expression higher than the average of the study. Figure originally published in Haematologica.4 
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KEY MESSAGES FOR CLINICAL PRACTICE
1 LIN28B expression levels stratify JMML patients into groups with different clinical outcomes.
2 The identification of high LIN28B levels in different leukaemia entities, together with its absence in normal 
tissue after birth, make LIN28B an excellent target for development of novel, specific therapeutics.
